{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:58:34Z","timestamp":1761562714136},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00277-020-04351-5","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T08:03:09Z","timestamp":1606291389000},"page":"1079-1085","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study"],"prefix":"10.1007","volume":"100","author":[{"given":"Bernard","family":"Regidor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Swift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Eades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsiye","family":"Emamy-Sadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"4351_CR1","doi-asserted-by":"publisher","first-page":"v155","DOI":"10.1093\/annonc\/mdq178","volume":"21","author":"J-L Harousseau","year":"2010","unstructured":"Harousseau J-L, Dreyling M (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v155\u2013v157. https:\/\/doi.org\/10.1093\/annonc\/mdq178","journal-title":"Ann Oncol"},{"key":"4351_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cts.12532","volume":"11","author":"D Ritchie","year":"2017","unstructured":"Ritchie D, Colonna M (2017) Mechanisms of Action and Clinical Development of Elotuzumab. Clinical and Translational Science 11:261\u2013266. https:\/\/doi.org\/10.1111\/cts.12532","journal-title":"Clinical and Translational Science"},{"key":"4351_CR3","doi-asserted-by":"publisher","unstructured":"Campbell KS, Cohen AD, Pazina T (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Frontiers in Immunology. https:\/\/doi.org\/10.3389\/fimmu.2018.02551","DOI":"10.3389\/fimmu.2018.02551"},{"key":"4351_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/nejmoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373:621\u2013631. https:\/\/doi.org\/10.1056\/nejmoa1505654","journal-title":"N Engl J Med"},{"key":"4351_CR5","unstructured":"Bristol-Myers Squibb Company. Empliciti (elotuzumab) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761035s008lbl.pdf. Revised November 2018. Accessed April 16, 2020."},{"key":"4351_CR6","doi-asserted-by":"publisher","unstructured":"Berenson J, Martinez D, Spektor T, et al (2019) A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed\/ Refractory Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia. https:\/\/doi.org\/10.1016\/j.clml.2019.09.413","DOI":"10.1016\/j.clml.2019.09.413"},{"key":"4351_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/ejh.13058","volume":"100","author":"Z Gross","year":"2018","unstructured":"Gross Z, Rahbari A, Wirtschafter E et al (2018) Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study. Eur J Haematol 100:621\u2013623. https:\/\/doi.org\/10.1111\/ejh.13058","journal-title":"Eur J Haematol"},{"key":"4351_CR8","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/jco.2017.35.15_suppl.8002","volume":"35","author":"J Laubach","year":"2017","unstructured":"Laubach J, Nooka AK, Cole C et al (2017) An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma. J Clin Oncol 35:8002\u20138002. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.8002","journal-title":"J Clin Oncol"},{"key":"4351_CR9","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/blood-2019-124870","volume":"134","author":"AJ Yee","year":"2019","unstructured":"Yee AJ, Laubach JP, Campagnaro EL et al (2019) A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood 134:3169\u20133169. https:\/\/doi.org\/10.1182\/blood-2019-124870","journal-title":"Blood"},{"issue":"1","key":"4351_CR10","first-page":"15","volume":"134","author":"JP Knochel","year":"1981","unstructured":"Knochel JP (1981) Hypophosphatemia. West J Med 134(1):15\u201326","journal-title":"West J Med"},{"key":"4351_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jbspin.2009.12.002","volume":"77","author":"B Bouvard","year":"2010","unstructured":"Bouvard B, Royer M, Chappard D et al (2010) Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine 77:120\u2013124. https:\/\/doi.org\/10.1016\/j.jbspin.2009.12.002","journal-title":"Joint Bone Spine"},{"key":"4351_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","volume":"118","author":"A Gaasbeek","year":"2005","unstructured":"Gaasbeek A, Meinders AE (2005) Hypophosphatemia: An update on its etiology and treatment. The American Journal of Medicine 118:1094\u20131101. https:\/\/doi.org\/10.1016\/j.amjmed.2005.02.014","journal-title":"The American Journal of Medicine"},{"key":"4351_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-200001000-00001","volume":"79","author":"R Subramanian","year":"2000","unstructured":"Subramanian R, Khardori R (2000) Severe Hypophosphatemia: Pathophysiologic Implications, Clinical Presentations, and Treatment. Medicine 79:1\u20138. https:\/\/doi.org\/10.1097\/00005792-200001000-00001","journal-title":"Medicine"},{"key":"4351_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00277-006-0095-3","volume":"85","author":"M Umeda","year":"2006","unstructured":"Umeda M, Okuda S, Izumi H et al (2006) Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma. Ann Hematol 85:469\u2013473. https:\/\/doi.org\/10.1007\/s00277-006-0095-3","journal-title":"Ann Hematol"},{"key":"4351_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.beha.2005.01.008","volume":"18","author":"A Dispenzieri","year":"2005","unstructured":"Dispenzieri A, Kyle RA (2005) Multiple myeloma: clinical features and indications for therapy. Best Practice & Research Clinical Haematology 18:553\u2013568. https:\/\/doi.org\/10.1016\/j.beha.2005.01.008","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"4351_CR16","unstructured":"Celgene Corporation. Revlimid (lenalidomide) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021880s028lbl.pdf . Accessed 16 April 2020"},{"key":"4351_CR17","unstructured":"Amgen Inc. Kyprolis (carfilzomib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202714s025lbl.pdf . Revised February 2019. Accessed 16 April 2020"},{"key":"4351_CR18","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1182\/blood.v120.21.4083.4083","volume":"120","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Hansen E, Steward D et al (2012) Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM). Blood 120:4083\u20134083. https:\/\/doi.org\/10.1182\/blood.v120.21.4083.4083","journal-title":"Blood"},{"key":"4351_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","volume":"103","author":"G Liamis","year":"2010","unstructured":"Liamis G, Milionis HJ, Elisaf M (2010) Medication-induced hypophosphatemia: a review Qjm 103:449\u2013459. https:\/\/doi.org\/10.1093\/qjmed\/hcq039","journal-title":"Medication-induced hypophosphatemia: a review Qjm"},{"key":"4351_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4065\/81.8.1047","volume":"81","author":"MQ Lacy","year":"2006","unstructured":"Lacy MQ, Dispenzieri A, Gertz MA et al (2006) Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clin Proc 81:1047\u20131053. https:\/\/doi.org\/10.4065\/81.8.1047","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"4351_CR21","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT et al (2012) (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u20133092. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"key":"4351_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2147\/tcrm.s1351","volume":"4","author":"G Birgegard","year":"2008","unstructured":"Birgegard G (2008) Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag 4:527\u2013539. https:\/\/doi.org\/10.2147\/tcrm.s1351","journal-title":"Ther Clin Risk Manag"},{"key":"4351_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/mnh.0000000000000329","volume":"26","author":"H Zoller","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B (2017) Iron-induced hypophosphatemia. Curr Opin Nephrol Hypertens 26:266\u2013275. https:\/\/doi.org\/10.1097\/mnh.0000000000000329","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4351_CR24","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793\u20131803. https:\/\/doi.org\/10.1002\/jbmr.1923","journal-title":"J Bone Miner Res"},{"key":"4351_CR25","unstructured":"Baxter Healthcare Corporation. IFEX (ifosfamide) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019763s017lbl.pdf. Revised March 2012. Accessed 27 April 2020"},{"key":"4351_CR26","unstructured":"Celgene Corporation. VIDAZA (azacytidine for injection). U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050794s011lbl.pdf. Revised August 2008. Accessed 27 April 2020"},{"key":"4351_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1053\/jhep.2002.35069","volume":"36","author":"L Schmidt","year":"2002","unstructured":"Schmidt L (2002) Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 36:659\u2013665. https:\/\/doi.org\/10.1053\/jhep.2002.35069","journal-title":"Hepatology"},{"key":"4351_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/08998280.2019.1688624","volume":"33","author":"KN Ramakrishna","year":"2019","unstructured":"Ramakrishna KN, Shah A, Martinez-Balzano CD (2019) Massively elevated creatine kinase levels in antihistamine-induced rhabdomyolysis. Baylor University Medical Center Proceedings 33:44\u201346. https:\/\/doi.org\/10.1080\/08998280.2019.1688624","journal-title":"Baylor University Medical Center Proceedings"},{"key":"4351_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1345\/aph.1c241","volume":"37","author":"CE Haas","year":"2003","unstructured":"Haas CE, Magram Y, Mishra A (2003) Rhabdomyolysis and Acute Renal Failure following an Ethanol and Diphenhydramine Overdose. Ann Pharmacother 37:538\u2013542. https:\/\/doi.org\/10.1345\/aph.1c241","journal-title":"Ann Pharmacother"},{"key":"4351_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5414\/cnp68093","volume":"68","author":"C Matsunaga","year":"2007","unstructured":"Matsunaga C, Izumi S, Furukubo T et al (2007) Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin Nephrol 68:93\u201398. https:\/\/doi.org\/10.5414\/cnp68093","journal-title":"Clin Nephrol"},{"issue":"4","key":"4351_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1067\/mcp.2002.121857","volume":"71","author":"F Schiodt","year":"2002","unstructured":"Schiodt F, Peter O, Christensen E et al (2002) The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. Clin Pharmacol Ther 71(4):221\u2013225. https:\/\/doi.org\/10.1067\/mcp.2002.121857","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"4351_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/j.1552-4604.1986.tb02946.x","volume":"26","author":"GT Blyden","year":"1986","unstructured":"Blyden GT, Greenblatt DJ, Scavone JM, Shader RI (1986) Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration. The Journal of Clinical Pharmacology 26(7):529\u2013533. https:\/\/doi.org\/10.1002\/j.1552-4604.1986.tb02946.x","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"1","key":"4351_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000199257","volume":"32","author":"L Smith","year":"1985","unstructured":"Smith L (1985) Clinical Pharmacology of Famotidine. Digestion 32(1):15\u201323. https:\/\/doi.org\/10.1159\/000199257","journal-title":"Digestion"},{"key":"4351_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1523-1755.2004.00359.x","volume":"65","author":"L Andrade","year":"2004","unstructured":"Andrade L, Rebou\u00e7as NA, Seguro AC (2004) Down-regulation of Na transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia. Kidney Int 65:175\u2013183. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00359.x","journal-title":"Kidney Int"},{"key":"4351_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","volume":"64","author":"B Balasa","year":"2014","unstructured":"Balasa B, Yun R, Belmar NA et al (2014) Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways. Cancer Immunol Immunother 64:61\u201373. https:\/\/doi.org\/10.1007\/s00262-014-1610-3","journal-title":"Cancer Immunol Immunother"},{"key":"4351_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/cbr.2005.20.11","volume":"20","author":"W Quan","year":"2005","unstructured":"Quan W, Ramirez M, Taylor C et al (2005) Administration of High-Dose Continuous Infusion Interleukin-2 to Patients Age 70 or Over. Cancer Biotherapy and Radiopharmaceuticals 20:11\u201315. https:\/\/doi.org\/10.1089\/cbr.2005.20.11","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"key":"4351_CR37","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1200\/jco.1988.6.7.1170","volume":"6","author":"GA Kozeny","year":"1988","unstructured":"Kozeny GA, Nicolas JD, Creekmore S et al (1988) Effects of interleukin-2 immunotherapy on renal function. J Clin Oncol 6:1170\u20131176. https:\/\/doi.org\/10.1200\/jco.1988.6.7.1170","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04351-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T09:40:47Z","timestamp":1615801247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4351"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04351-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"This study was approved by the institutional review board and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All patients provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki 1964 and its later amendments, and International Conference on Harmonization Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}